Filing Details

Accession Number:
0000947871-17-000762
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-09-28 17:31:21
Reporting Period:
2017-09-26
Accepted Time:
2017-09-28 17:31:21
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1472343 Roka Bioscience Inc. ROKA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1055949 D Samuel Isaly 601 Lexington Avenue
54Th Floor
New York NY 10022
No No Yes No
1055951 Orbimed Advisors Llc 601 Lexington Avenue
54Th Floor
New York NY 10022
No No Yes No
1432241 Orbimed Capital Gp Iii Llc 601 Lexington Avenue
54Th Floor
New York NY 10022
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $0.001 Per Share Disposition 2017-09-26 74,096 $1.03 722,215 No 4 S Indirect See Footnotes
Common Stock, Par Value $0.001 Per Share Disposition 2017-09-26 706 $1.03 6,877 No 4 S Indirect See Footnotes
Common Stock, Par Value $0.001 Per Share Disposition 2017-09-27 52,301 $0.92 669,914 No 4 S Indirect See Footnotes
Common Stock, Par Value $0.001 Per Share Disposition 2017-09-27 498 $0.92 6,379 No 4 S Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares of the Issuer's common stock ("Shares") were sold in multiple transactions at prices ranging from $0.92 to $1.13 inclusive. Upon request, the Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission (the "SEC") full information regarding the Shares sold at each separate price within the range set forth in this footnote.
  2. The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $0.88 to $0.97 inclusive. Upon request, the Reporting Person undertake to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares sold at each separate price within the range set forth in this footnote.
  3. These securities are held of record by OrbiMed Private Investments III, LP ("OPI III") and may be deemed to be indirectly beneficially owned by OrbiMed Capital GP III LLC ("GP III"), OrbiMed Advisors LLC ("Advisors") and Samuel D. Isaly ("Isaly"). GP III is the sole general partner of OPI III. Advisors, a registered adviser under the Investment Advisers Act of 1940, as amended, is the sole managing member of GP III. By virtue of such relationships, GP III and Advisors may be deemed to have voting and investment power with respect to the securities held by OPI III noted above.
  4. Isaly, a natural person, may also be deemed to have voting and investment power with respect to the securities held by OPI III noted above in his capacity as the managing member of, and holder of a controlling interest, in Advisors. As a result, each of GP III, Advisors and Isaly may be deemed to have beneficial ownership of the securities held by OPI III.
  5. These securities are held of record by OrbiMed Associates III, LP ("Associates III") and may be deemed to be indirectly beneficially owned by Advisors and Isaly. Advisors is the sole general partner of Associates III. Isaly is the managing member of, and holder of a controlling interest in, Advisors. By virtue of such relationship, Advisors and Isaly may be deemed to have voting and investment power with respect to the securities held by Associates III noted above. As a result, each of Advisors and Isaly may be deemed to have beneficial ownership of the securities held by Associates III.
  6. This report on Form 4 is jointly filed by GP III, Advisors and Isaly. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Persons are beneficial owners for the purpose of Section 16 of the Exchange Act, or for any other purpose.